Aficamten is an investigational, oral, small molecule cardiac myosin inhibitor. It was designed to reduce the hypercontractility associated with HCM by blocking myosin from pulling, resulting in less contraction, or fewer hands on the rope. In preclinical models, aficamten reversed and reduced thickening and stiffening of the heart.

Aficamten is the subject of SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), a Phase 3 randomized, placebo-controlled, double-blind, multi-center clinical trial designed to evaluate aficamten in patients with symptomatic oHCM on background medical therapy for 24 weeks.

Learn more about clinical trials for aficamten

Aficamten is an investigational product and is not approved by any regulatory agency. Safety and effectiveness have not been established.

Discover our other drug candidates

Omecamtiv Mecarbil

Omecamtiv mecarbil is designed to directly target the contractile mechanism, or pumping function of the heart.

About Omecamtiv Mecarbil


Reldesemtiv is an investigational fast skeletal muscle troponin activator for the potential treatment of amyotrophic lateral sclerosis (ALS).

About Reldesemtiv


CK-136 is an investigational cardiac troponin activator for the potential treatment of patients with heart failure with reduced ejection fraction (HFrEF).

About CK-136

  1. 1. Heart Failure | National Heart, Lung, and Blood Institute (NHLBI) [Internet]. 2019. Available at: Accessed March 22, 2019.
  2. 2. Maron, MS, Hellawell, JL, Lucove, JC, Farzaneh-Far, R and Olivotto, I (2016). “Occurrence of clinically diagnosed hypertrophic cardiomyopathy in the United States.” The American journal of cardiology 117(10): 1651-1654.